Lycopodium Limited AI Stock Analysis
Lycopodium Limited (LW1) AI Stock Analysis
Lycopodium Limited
(Frankfurt:LW1)
No summary available
Lycopodium Limited (LW1) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 557.99M
- Dividend Yield
- 3.31%
- Average Volume (3M)
- 269
- Price to Earnings (P/E)
- 19.8
- Beta (1Y)
- 0.42
- Revenue Growth
- 9.72%
- EPS Growth
- -7.72%
- Country
- Germany
- Employees
- 1,300
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Engineering & Construction
Lycopodium Limited Business Overview & Revenue Model
Company Description
Established in 1992 and based in East Perth, Australia, Lycopodium Limited provides expert engineering and complete project execution solutions across the natural resources, infrastructure, and industrial manufacturing sectors. The company operates t...
Lycopodium Limited Earnings Call Summary
The call presents a strongly positive operational and financial picture: record revenue, solid margins hitting NPAT targets, robust cash and equity growth, and an expanding project and study pipeline with early and confident FY'27 guidance. Key achievements include numerous project awards, a growing Americas footprint and substantial increases in committed contracts and studies. Primary risks flagged are execution and sovereign risks in foreign jurisdictions, about 30% of FY'27 revenue still uncommitted, capacity constraints to meet demand (requiring further hiring and office expansion), and regional concentration (58% revenue from Africa). On balance, the highlights substantially outweigh the lowlights, though execution of the strong pipeline remains critical to realize guidance.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Lycopodium has brought forward FY‑27 guidance of AUD 540–580m revenue (midpoint AUD 560m, roughly +50% on FY‑26 revenue of $377.5m) and NPAT of $54–58m (consistent with its ~±10% NPAT margin target); management says just under 70% of FY‑27 revenue is already locked in (within ~AUD 661m of committed contracts), with >90 studies in the pipeline and six‑month momentum metrics including committed contracts +59%, revenue opportunity pipeline +8%, managed CapEx +32% and studies up twofold—backed by FY‑26 results of EBITDA $59.5m (15.7%), PBT $52.5m, NPAT $40.2m (10.6%), EPS $1.01, equity $170.7m (+13%), ROE 25%, cash $106.2m, NTA $3.92/share and minimal debt.
Lycopodium Limited Peers Comparison
Overall Rating
AU:MND80Outperform
AU:NWH80Outperform
AU:GNG74Outperform
AU:CVL60Neutral
AU:DOW59Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | AUD 3.41B | 26.93 | 22.77% | 3.18% | 29.43% | 50.05% | |
| 80Outperform | AUD 3.09B | 19.91 | 23.03% | 3.43% | 31.39% | 451.49% | |
| 74Outperform | AUD 1.43B | 32.74 | 53.12% | 3.46% | 2.95% | 12.85% | |
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| 60Neutral | AUD 837.13M | 16.47 | 9.25% | 3.66% | 11.40% | 22.22% | |
| 59Neutral | AUD 4.66B | 21.79 | 11.01% | 4.02% | -7.37% | 59.81% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:LW1 | Lycopodium Limited | 12.30 | 5.38 | 77.85% | |
| AU:DOW | Downer EDI Limited | 7.26 | -0.09 | -1.20% | |
| AU:MND | Monadelphous Group Limited | 33.94 | 8.64 | 34.13% | |
| AU:NWH | NRW Holdings Limited | 6.70 | 1.89 | 39.21% | |
| AU:GNG | GR Engineering Services Ltd | 7.52 | 3.75 | 99.36% | |
| AU:CVL | Civmec Singapore Limited Shs Chess Deposit Interests Repr 1 Sh | 1.64 | 0.32 | 24.34% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
